New eye drop targets Mite-Related eyelid inflammation in phase 2 trial
NCT ID NCT06720896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new eye drop (APT-001, containing spinosad 1.8%) for blepharitis, a condition causing red, irritated eyelids often linked to tiny mites. About 100 people with symptoms will receive either the active drop or a placebo. The goal is to see if the treatment clears eyelid debris and redness safely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEPHARITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Rudy Gutierrez Diaz Sede Central
Guatemala City, Guatemala
-
EyeScan, Imágenes Diagnósticas Oculares, S. A.
Guatemala City, Guatemala
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can plant extracts on a gauze tame eyelid bacteria?
- Phone AI could spot eye disease in remote areas
- Eyelid wipes zap Mite-Caused eye inflammation in new study
- New eye device aims to soothe stubborn eyelid inflammation
- Can colored light masks soothe dry, irritated eyes?
- New eye ointment aimed at soothing chronic eyelid inflammation